Likacin (Amikacin)

• Likacin is a topical aminoglycoside used to manage bacterial skin and soft‑tissue infections.
• Complicated skin and soft‑tissue infections: reduces bacterial load and promotes healing.
• Burn wound infections: eradicates Gram‑negative pathogens from burn areas.
• Post‑surgical wound infections: prevents colonisation by susceptible bacteria.
• Diabetic foot ulcers: helps control infection in chronic ulcerative lesions.
• Traumatic skin abrasions: limits bacterial proliferation and reduces risk of secondary infection.

• Amikacin binds to the bacterial 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis. This action disrupts essential cellular functions, leading to bactericidal activity against aerobic Gram‑negative organisms and some Gram‑positive strains. The drug’s high affinity for the ribosomal binding site confers activity even against many aminoglycoside‑resistant bacteria. By interfering with translation, amikacin rapidly reduces viable bacterial counts, making it effective for acute infections where prompt bacterial eradication is required.

Topical application of amikacin may be associated with local and systemic adverse reactions.

Common Side Effects

• Local irritation: redness or burning at the application site.
• Pruritus: itching around the treated area.
• Dermatitis: mild rash or eczema‑like eruption.
• Pain: discomfort or tenderness at the site.

Serious or Rare Side Effects

• Allergic contact dermatitis: severe skin reaction with swelling and vesicles.
• Systemic nephrotoxicity: impaired kidney function if absorbed over large areas.
• Ototoxicity: hearing loss or balance disturbances in rare cases of systemic exposure.

When using Likacin, healthcare professionals should observe several precautionary measures to minimise risks.

• Renal function: assess baseline kidney status and monitor if extensive skin areas are treated.
• Hearing: evaluate auditory function in patients with pre‑existing ear disorders.
• Pregnancy and lactation: prescribe only when benefit outweighs potential risk to fetus or infant.
• Allergy: avoid use in individuals with known hypersensitivity to amikacin or other aminoglycosides.
• Resistance: limit application to infections confirmed to be caused by susceptible organisms to prevent resistance development.
• Store at room temperature: keep in original container, protect from moisture and light.

Amikacin may interact with other medicines, altering its safety profile or efficacy.

Major Interactions (Avoid)

• Nephrotoxic agents (e.g., vancomycin, amphotericin B, loop diuretics): increased risk of kidney injury.
• Ototoxic drugs (e.g., gentamicin, streptomycin, furosemide): heightened potential for hearing loss.
• Neuromuscular blocking agents (e.g., succinylcholine, pancuronium): may potentiate muscle weakness.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may modestly affect renal clearance of amikacin.
• Other aminoglycosides: concurrent use can increase cumulative toxicity.
• Diuretics: monitor electrolytes and renal function during combined therapy.